AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04814537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Local Anesthetic Agent
Study NCT04814537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Local Anesthetic Agent
Study NCT05745727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-115
Description: Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8
Study NCT05745727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
Study NCT05696340 — intervention group
Intervention type: OTHER
Intervention: semi-structured interview
Description: Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis.~The number of participants cannot be determined in advance; it will be determined after data saturation.
Study NCT05011461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Oil
Description: Almond Oil Pressed Cold
Study NCT05011461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Almond Oil
Description: Almond Oil Pressed Cold
Study NCT05337722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SFT 2.0
Description: The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person
Study NCT05337722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
Study NCT04541069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Communication and Emotional Skill Development (SCESD) module
Description: The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
Study NCT05565547 — intervention group
Intervention type: DEVICE
Intervention: META
Description: The META device is used for a comprehensive ophthalmic examination.
Study NCT05565547 — intervention group
Intervention type: DEVICE
Intervention: Commercial devices
Description: Commercial devices (including near and far eye charts, refractometer, optical biometry, slit lamp microscopy, fundus camera and OCT) are used for a comprehensive ophthalmic examination.
Study NCT05491889 — intervention group
Intervention type: BIOLOGICAL
Intervention: trans arterial chemoembolization
Description: trans arterial chemoembolization in patient with partial portal vein thrombosis
Study NCT05688657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: Monthly Replacement Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
Study NCT05688657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: Daily Disposable Toric Silicone Hydrogel Contact Lens 15 minutes of daily wear
Study NCT05194488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Patients will receive low-level laser therapy on the temporomandibular joint disc
Study NCT05194488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Patients will receive Botulinum toxin type A injection into the lateral pterygoid muscle under Electromyography (EMG) guidance.
Study NCT05194488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior repositioning appliance
Description: Patients will receive hard maxillary anterior repositioning appliance.
Study NCT05227235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Telemedicine
Description: Clinical consultation with patient performed with 3D Telemedicine
Study NCT05227235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2D Telemedicine
Description: Clinical consultation with patient performed with 2D Telemedicine as standard of care
Study NCT04964388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: Diabetes medication
Study NCT06362239 — intervention group
Intervention type: OTHER
Intervention: Study Surveys
Description: Participants will complete study surveys as their participation in the research study. Study staff will collect clinical and demographic information from the electronic medical records. The enrollment in this intervention will not be decided by research enrollment, but would naturally occur regardless of enrollment in the study.
Study NCT05453799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vudalimab
Description: Given IV
Study NCT05357183 — intervention group
Intervention type: DRUG
Intervention: PEG-IFN
Description: PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
Study NCT04210570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Memsorb
Description: Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit
Study NCT04210570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemical granulate absorber
Description: Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
Study NCT04210570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemical granulate absorber
Description: Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
Study NCT04966221 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI scan
Description: Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
Study NCT05573360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NGF5-A test formulation
Description: One drop of investigational product instilled on the eye
Study NCT05260021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirzepatide Dose 1
Description: Administered SC
Study NCT05260021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide Dose 1
Description: Administered SC
Study NCT05260021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide Dose 2
Description: Administered SC
Study NCT05260021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT06242795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% Hypertonic Saline via nebulization
Description: Twice a day treatment with nebulized 7% HS for 2 weeks as part of airway clearance
Study NCT04978623 — intervention group
Intervention type: OTHER
Intervention: high frequency ultrasound
Description: high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome
Study NCT04632199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111In-IPN01087 Low dose
Description: Administered once via slow intravenous injection.
Study NCT04632199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111In-IPN01087 High dose
Description: Administered once via slow intravenous injection.
Study NCT04901507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Voutia System
Description: Participants will wear the Voutia System oral irrigation device continuously through the day and night, removing for cleaning and if otherwise necessary, but not for time extending beyond six-eight hours.
Study NCT02723435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Given PO
Study NCT05241639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam
Description: Pentacam (Oculus GmbH, Wetzlar, Germany) is used to image both the anterior and posterior corneal surfaces, providing a complete pachymetry map. Furthermore, it includes the corneal densitometry program in its software, which detects the amount of backscattered light in different regions of the cornea, providing an objective assessment of corneal transparency, and it is hypothesized that corneal densitometry may be altered in the presence of a systemic inflammatory disease, even in the absence of any corneal haze or scar
Study NCT05959005 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention.
Study NCT05019976 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 0
Description: Dose Per Fraction (Each Radiation Treatment): 3.2Gy to 2.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 44.8Gy to 33.6Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 14
Study NCT05019976 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 1
Description: Dose Per Fraction (Each Radiation Treatment): 4.2Gy to 3.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 42Gy to 32Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 10
Study NCT05019976 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 2
Description: Dose Per Fraction (Each Radiation Treatment): 5.2Gy to 4.2Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 39.2Gy to 29.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 7
Study NCT05019976 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 3
Description: Dose Per Fraction (Each Radiation Treatment): 6.8Gy to 5.4Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 34Gy to 27Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 5
Study NCT05019976 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation - Dose Level 4
Description: Dose Per Fraction (Each Radiation Treatment): 10Gy to 7.8Gy (minimal dose) depending on what study doctor prescribes~Total Dose of Radiation for Treatment Period: 30Gy to 23.4Gy (minimal dose) depending on what study doctor prescribes~Total Number of Radiation Treatments: 3
Study NCT05495295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhOx430
Description: A standard 3 + 3 design will be followed. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval.
Study NCT06334133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadisegliatin 800 mg QD
Description: Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
Study NCT06447376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Single dose of prophylactic siltuximab, 11mg/kg, started 1 hour prior (+/- 60 minutes) to the infusion of epcoritamab.
Study NCT06447376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab dosing for Diffuse Large B-cell Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 48mg~* Cycle 1, Day 22 = 48mg~* Cycles 2 \& 3, Day 1 = 48mg~* Cycles 2 \& 3, Day 8 = 48mg~* Cycles 2 \& 3, Day 15 = 48mg~* Cycles 2 \& 3, Day 22 = 48mg~* Cycles 4-9, Day 1 = 48mg~* Cycles 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg~Epcoritamab dosing for Follicular Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 3mg~* Cycle 1, Day 22 = 48mg~* Cycle 2 \& 3, Day 1 = 48mg~* Cycle 2 \& 3, Day 8 = 48mg~* Cycle 2 \& 3, Day 15 = 48mg~* Cycle 2 \& 3, Day 22 = 48mg~* Cycle 4-9, Day 1 = 48mg~* Cycle 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg
Study NCT06334133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadisegliatin 800 mg BID
Description: Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
Study NCT06334133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05681728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
Study NCT05681728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
Study NCT05573360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NGF4-B test formulation
Description: One drop of investigational product instilled on the eye
Study NCT05573360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-B test formulation
Description: One drop of investigational product instilled on the eye
Study NCT05681728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
Study NCT05681728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
Study NCT04207710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gebauer's Pain Ease Top Aerosol Mist Spray
Description: Topical refrigerant spray
Study NCT04207710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gebauer's Ethyl Chloride
Description: Topical refrigerant spray
Study NCT05573360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NGF6-E test formulation
Description: One drop of investigational product instilled on the eye
Study NCT04870320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endeavor: Computer-Based Cognitive Stimulation Intervention
Description: Endeavor application will be utilized by participant on iPad
Study NCT04870320 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Words!: Computer-Based Cognitive Stimulation Intervention
Description: Words! application will be utilized by participant on iPad
Study NCT04870320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) Questionnaires
Description: Standardized QOL questionnaire will be administered at each study visit
Study NCT04870320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life (QOL) Questionnaires
Description: Standardized QOL questionnaire will be administered at each study visit
Study NCT05573360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Systane eye drop
Description: One drop of commercial product instilled on the eye
Study NCT04914000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Materials
Description: Self-help booklet targeted by cancer type to increase smoking cessation motivation
Study NCT05887804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cells (UC-MSC)
Description: Group 1 was injected UC-MSC 2 million cells/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
Study NCT05887804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM)
Description: Group 2 was injected UC-CM 1 mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
Study NCT05887804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide (TA)
Description: Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
Study NCT05987618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral appliance with elastic bands
Description: The elastic bands are attached to hooks on both the upper and lower appliance, and on both sides. The elastic bands will be carefully selected not to interfere with retention of the oral appliance. The strongest elastic bands that do not interfere with retention of the oral appliance will be chosen, probably within the range of 85-170 grams (3/8 - 3/16).
Study NCT05987618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral appliance without elastic bands
Description: The oral appliance without the elastic bands.
Study NCT05121246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB05 (Proposed palivizumab biosimilar)
Description: Single IM dose of 3 mg/kg
Study NCT05121246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Synagis®
Description: Single IM dose of 3 mg/kg
Study NCT05121246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Synagis®
Description: Single IM dose of 3 mg/kg
Study NCT05006612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle.
Study NCT05814029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement for Ankle
Description: The participant will assume a lunge position on a rigid serving table with the relevant extremity in a weight-bearing stance and the foot in a neutral position. An inelastic belt will be placed around the clinician's waist, flush with the lower edge of the medial malleolus, around the distal tibia and fibula. The clinician will stabilize the talus and forefoot with the web spacing of the hands and pressure dimensions on the talus and forefoot, and maintain posterior to anterior sliding of the tibia over the talus using the arch. The clinician will continue to apply pressure while the person is reporting discomfort and/or while the lunge moves, which will continue until the end of the range of motion. Mobilization will be performed as a 3 set of 10 repetitions.
Study NCT05019560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
Study NCT05019560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: IFT response, hemodynamics and BIS value were recorded during intubation period. Then the data acquisition was stopped and the isolated forearm cuff deflated. IFT values were noted by two independent observers
Study NCT05547711 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: drawing blood
Description: drawing blood annually measurement of heartrate variability annually determine weight with a bioimpedance scale
Study NCT05579535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait training exercises
Description: walking exercises in different directions
Study NCT05579535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait training exercises
Description: walking exercises in different directions
Study NCT05840133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention was required for patients or control group in this study
Description: The patient was treated normally and no intervention was required in this study
Study NCT04742543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SootheVR: AppliedVR, Los Angeles, California a head-mounted display
Description: For the study group, virtual reality content will be shown to the participant for the duration of the conization procedure through a head-mounted display, RelieVRTM. The default VR content for the trial will be swimming with dolphins or any other content chosen by the participant
Study NCT06210984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low caffeine dose
Description: 2 mg/kg dose of caffeine in pill form
Study NCT06210984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate caffeine dose
Description: 5 mg/kg dose of caffeine in pill form